Mölnlycke Health Care and Transdiagen announce research collaboration to drive innovation in wound care

GOTHENBURG, Sweden, October 24, 2024 /PRNewswire/ — Today, Mölnlycke Health Care, a global leading MedTech company specializing in wound care and management, announces a research collaboration with Transdiagen (TDG), a precision medicine company developing medicines and diagnostics for chronic wound healing and tissue regeneration. The collaboration aims to use TDG’s new wound gene signatures to further investigate Mölnlycke’s products.

Emma Wright, EVP Chief Medical Officer, Mölnlycke, says: “We are excited about our research collaboration with TDG, which will allow us to be at the forefront of the advanced understanding of chronic wounds. This opens up a wealth of opportunities for future innovation in the underfunded and under-prioritized field of wound care.”

James Harding, CEO of Transdiagen added: “We are pleased to be working with Mölnlycke on this R&D programme. This collaboration will give Mölnlycke access to TDG’s new models to generate functional insights into the mechanism of action of innovative and biological wound treatment solutions. We believe this marks a new chapter in the approach to data-driven, evidence-based product development for the treatment of complex wounds.”

The collaboration will start soon.

For more information please contact:

Jennifer Doak

Global Communications Director Wound Care
Email: [email protected]

Phone: +1 678 206 6179

This information is brought to you by Cision http://news.cision.com

https://news.cision.com/molnlycke/r/molnlycke–health-care-and-transdiagen-announce-research-collaboration-to-drive-innovation-in-wound-,c4056056

The following files are available for download:

View original content: https://www.prnewswire.co.uk/news-releases/molnlycke-health-care-and-transdiagen-announce-research-collaboration-to-drive-innovation-in-wound-care-302286130 . html